Celebrex, Vioxx GI Safety Data To Be Reviewed By FDA Committee Feb. 7-8
Executive Summary
Applications to modify the NSAID class gastrointestinal safety labeling for the COX-2 inhibitors Celebrex and Vioxx will be reviewed by FDA's Arthritis Advisory Committee Feb. 7-8.
You may also be interested in...
Pharmacia Bextra Will Test COX-2 Market; Valdecoxib Clears FDA Nov. 16
Pharmacia's Bextra (valdecoxib) launch will test the hypothesis that the recent slow-down in the growth of Celebrex reflects a traditional nonsteroidal anti-inflammatory drug product lifecycle
Pharmacia Could See Double COX-2 NME Drug Approvals In 2001
Pharmacia could gain approval of two COX-2 inhibitor drugs that are new molecular entities by late 2001.
Pharmacia Could See Double COX-2 NME Drug Approvals In 2001
Pharmacia could gain approval of two COX-2 inhibitor drugs that are new molecular entities by late 2001.